Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
A 32-year-old male with hair loss cannot use finasteride due to erectile dysfunction and minoxidil due to scalp psoriasis. He seeks alternative treatments for his condition.
The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.
Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.
Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.
New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.
The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A user diagnosed with Crohn's disease is concerned it might contribute to balding. They have been using keto shampoo, finasteride, and oral minoxidil, which improved their hair but not significantly.
Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.
The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.
The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.
The conversation discusses managing hair loss and scalp issues, with users sharing experiences using treatments like dutasteride, finasteride, ketoconazole, sulfur soap, and topical anti-androgens. Suggestions include trying sulfur soap, scalp massages, spironolactone, and dietary changes to reduce sebum production and dandruff.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
Two twins who used Minoxidil, finasteride and dermarollers to treat their androgenic alopecia over a 10 month time period. The user is providing details on the process they use for dermarolling.
The conversation discusses hair loss, with users suggesting treatments like ketoconazole shampoo, finasteride, and dutasteride. Symptoms like burning and tenderness are mentioned, with recommendations to see a dermatologist for potential scarring alopecia.
Platelet-rich plasma (PRP) therapy for hair loss is expensive, painful, and often ineffective, with mixed reviews on its benefits. Alternatives like minoxidil, finasteride, and hair transplants are suggested as more reliable options.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.
The user is generally happy with their hair transplant results but has concerns about graft density and placement, particularly on the left temple and hairline. They are using finasteride and minoxidil inconsistently, plan to add Priorin, and are considering microneedling and PRP sessions for future care.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.